Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03414658 · ClinicalTrials.gov registry record · Phase 2

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Adrienne G. Waks.

Active
Registry status
Phase 2
Development phase
100
Enrollment target
17
Study locations

NCT03414658 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Adrienne G. Waks. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 17 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03414658, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Adrienne G. Waks.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
17
Study locations

Study Summary

This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

Conditions Studied

Breast Cancer

Interventions

  • DRUG Trastuzumab
  • DRUG Avelumab
  • DRUG Vinorelbine
  • DRUG Utomilumab

Study Locations (17)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan-Kettering Cancer Center - New York
  • Montefiore Medical Center - The Bronx

North Carolina

  • University of Carolina at Chapel Hill - Chapel Hill
  • Duke University Medical Center - Durham

Texas

  • Baylor College of Medicine - Houston
  • MD Anderson Cancer Center - Houston

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • University of California San Francisco - San Francisco

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Illinois

  • University of Chicago Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-06-21
Est. Completion 2026-05-31
Phase Phase 2

Sponsor

Adrienne G. Waks

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03414658

The ClinicalTrials.gov registry entry for NCT03414658 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Adrienne G. Waks, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.

NCT03414658 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT03414658 about?

NCT03414658 is a clinical study titled "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer". This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Uto...

What is the current status of trial NCT03414658?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-06-21. Estimated completion is 2026-05-31.

What conditions does trial NCT03414658 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03414658?

The interventions under investigation include: Trastuzumab (DRUG), Avelumab (DRUG), Vinorelbine (DRUG), Utomilumab (DRUG).

Who is sponsoring clinical trial NCT03414658?

This trial is sponsored by Adrienne G. Waks, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03414658 being conducted?

This trial has 17 study locations across Alabama, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.